OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Check out their website, I think their experiments have been on terminally-ill patients most recently and usual arrangements (on humans) before that. The later tests are unusual in that the patients must be certified they have a limited life (presumably because they need an autopsy) so it is not easy to determine the before/after (effectiveness) for the treatment, but I understood their tests of about 2-years ago were above expectations.
Bid/Merger
I suspect it is not OXB that is willing to consider a deal; rather that it is a Listing requirement that talks proceede. AK may be mistreating his (retail) shareholders as suggested above, but I suspect he'd rather be doing a deal or setting-up another trial, than talking to suits.
Resaults/Update
There may be some good news with the results so I'm in two minds about selling out; as often happens the sp rises in the weeks before the news -and these days news seems to be somewhat leaky for all stocks in general.
I hold OXB at an average about this level and wonder if trying to trade my position isn't risk-taking - as I don't think the price will slip to silly levels (eg 12p); what say you?

Afternoon All!

Enjoyed a lovely break from work last week especially the Super Reds victory
at Highbury (snigger! snigger! tee hee hee tee).

Getting back to today not I'm not surprised to see that the bid/merger talks
have been terminated and the sp has tumbled down past my forecast last week of
21p. Glad I sold up over a week ago and have not been tempted to rush back in
as yet.Hopefully I can dive back in and catch the next rise or maybe not.

Think it will be iteresting to see end of day buying (not sure today or tomorrow)

OH //go on/////SELL/////GET THE PRICE WAY DOWN///////then I can buy at low prices which i like to do with ALL my buys//////so go on sell sell////

The sp is starting to claw back some of its earlier losses and I would not
be surprised to see this continue today and tommorrow. The shares look cheap
at the present level and I am tempted to buy. However, I will continue to
resist and hope the sp falls another 15%-20% before I invest any money.

Any comments welcome on where you feel the share price will be by the end of
this week.

Impossible to say - esp when you have Citywire saying "13:59 Mon 07 Feb - Partner talks continue, says Oxford Biomedica boss". W/o any indication of other companies taking an interest then my guess is that the sp will not move much (or perhaps decline slowly) until the next Trovax update.

Pachandl

Good to hear from you again. Not sure I agree with all your above comments
regarding the sp.

I reckon that sp in this stock will remain volatile over the next month and
the remainder of this week will see steep rises or dips in the sp.

I'm hoping that the sp will continue to drop this week to enable me to climb
back on aboard. Such is the volatility of OXB just 2 weeks ago I would have
jumped at the chance of purchasing OXB at 0.1975p however, now I'm willing to
wait to see if it drop further.

I hope my strategy pays off. Greed is Good!

From Times

********************
Oxford BioMedica

BIOTECH investors do not take kindly to disappointments, so there was a degree of inevitability in the 20 per cent share price fall that followed news that merger talks between Oxford BioMedica and an unnamed suitor have come to nought.



It is the hope of many a stale bull that suitors from America, fortified by the higher stock market ratings on offer on Wall Street, might try to line up pipeline-bolstering deals on this side of the Atlantic. A deal involving Oxford BioMedica would certainly have furthered the argument nicely, but it was not to be. It would appear that the companys secret admirer could not agree a price with the co-founders Alan and Susan Kingsman.

That may leave the bulls seeking another champion to further their cause, but it is not necessarily bad news for BioMedica. The management is clearly open to offers, but unwilling to compromise on price.

With more than 20 million in the bank, and a promising anti-cancer vaccine nearing the end of four phase II clinical trials, the management can afford to wait. Work is also under way on treatments to cure Parkinsons disease and retionopathy, a form of blindness. The shares, down 5p at 19p, are still about 10 per cent higher than their level before news of merger talks broke, reflecting perhaps the emergence of Boris Jordan, the Russian hedge fund manager, on the share register. As with any biotech stock, the risks are very high, but Biomedicas diverse portfolio at least improves the chances of reward. Buy.
***********************************

Thanks Fred.

1701 - it looks like The Times has scotched chances of getting in at a lower price for the present. Not complaining! Stay lucky.

This volatility is so useful for making money.

Whenever it goes up significantly I reduce my holding & when it goes back down again, I use that profit to increase it again but I always keep an increasing core holding.

I think this company will win big in the end, it is not dependent on just 1 drug.

Apple

I agree with your comments 100%. There is plenty of money to be made on this
stock this year on the dips and rises.

Just read the article in 'The Times' and the buy recommendation Grrrrrrrrrr)
looks like my strategy of waiting for further dips in the sp this week has not
materialised as yet Grrrrrrrrrr).

Well done! To all those who continued to hold or buy after yesterday's heavy
fall in the sp.

Pachandl-I may live to regret not buying back in yesterday. There again I
may not? Greed is good (sometimes) Grrrrrrrrrrrrr!

Not positive whether this was posted earlier - but at least it suggests that I was initially right when guessing at Vernalis being the possible suitor.

...

http://news.independent.co.uk/business/news/story.jsp?story=608909
Oxford BioMedica dips 20% as merger fails
By Stephen Foley
08 February 2005


Oxford Biomedica is to pursue several further informal bid talks after the biotech company said yesterday that merger negotiations with its first suitor had collapsed.

The negotiations that have just been broken off are believed to have been with the acquisitive biotech company Vernalis. Sources said the talks stalled over a number of issues, including valuation. It is also understood that there was no agreement over the ongoing role of the company's founders, the husband and wife duo Professors Alan and Susan Kingsman.

Vernalis is chaired by Peter Fellner, the former chairman of Celltech, with a mission to consolidate the fragmented UK biotech sector.

The talks proved a "useful distraction", according to Professor Alan Kingsman, the chief executive, and are understood to have flushed out other expressions of interest. He said: "There are lots of smaller and larger companies active in looking for mergers and acquisitions. It never surprises me to get a call saying, 'Alan, let's have a chat about getting the companies together'."

Share in the group plunged 20 per cent on news that merger talks with the as yet mystery suitor had been called off. They closed down 5p at 19.5p, still 10 per cent higher than when rumours of a possible deal began to swirl. Speculative investors had been betting on a takeover by one of OXB's giant drug development partners, although analysts said a tie-up with a UK quoted or private biotech company was more likely.

OXB was set up by the Kingsmans as a spin-out from Oxford University in 1995, and it specialises in developing drugs using gene therapy. Its most advanced product, TroVax, which is in the second of the three phases of human trials necessary for approval, is a treatment for cancer.

Professor Alan Kingsman said several elements of the proposed merger were unsatisfactory, but that he would not have stood in the way of a deal that was in shareholders' best interests. "I am not pathologically possessive of Oxford BioMedica, although I am totally committed to it. I have no plans to step aside and I don't particularly want to, but if it is important for shareholder value then I would step aside.

"As the products move into phase III and beyond and the emphasis becomes commercial rather than technical, then it may be time to step aside, but discussions with partners are now still significantly technical."

OXB is hopeful that phase II trials results on TroVax, due this month, will show that it prolongs the life of patients suffering from colorectal cancer.

If nothing else, all this speculation has finally got the company noticed, there are even suggestions that there may be several other co's eyeing oxb up, so it could get very interesting. Another chance to get in below 20p I did not expect. Trovax valuation is key here and with conservative estimates being 50p per share I am definitely in for the longer term or until takeover.

'Top ah da morning to ya all'

Splish!, Splash!, Splosh!

Dived back in this morning at 8.30am with a 150,000 buy at 22.75p and still
got more in the war chest if the sp dips again. Still annoyed at myself for
not getting back in at earlier levels on Monday (Grrrrrrrrrrr!)

I'm off down to boots now to stock up on some tablets for high blood
pressure and dodgy tickers. I reckon I'll need them while waiting for
the Trovax and company results.

Afternoon All!

Splish, Splash, Splosh!

Dipped into the war chest again this morning to buy 31,260 at slightly just
over 22p and will be adding to my holding if the sp continues to dip.

I expect the volatility to remain in the sp until the Trovax results this month
and preliminary results expected on 3/03/05.

1704 - totally agree with your analysis. The difficulty is in predicting whether the sp will move northwards simply because it appears OXB are now "in play".

Pachandl- Good to hear from you. OXB is definetly ''in play''.
As others on this thread have stated several times the sp is
still underpriced and therefore, if the Trovax and
Preliminary results are good there should be some good rises in
the sp. I'm expecting to see more large buys rather than sells over the next
4 weeks.

I'm hoping to see 'buy' recommendations in the 'Investor Chronicle' or
Shares Magazine before the end of the month to send the sp beyond the
30p mark.

Come on OXB announce the Trovax results now!

Good to see a 'buy' of 850,000 go through at 3.10pm. I wonder if Boris Jordon
is continuing to build up his stake?.

'The Independent Newspaper' on 7/2/05 had an interesting article on OXB and
mentioned that Boris Jordon has recently met up with the OXB Board for
discussions. I wonder what these discussions were about? The article
also mentions that the Board have been holding talks for several weeks with
a number of different parties.

Expect to see more 850,000 plus 'buys' over the next few weeks.

Morning All!

Pleased to read this morning that the 'Money Week'Magazine included a summary
of 'The Times' newspaper's 'buy'recommendation earlier this week. However,
would have been more pleased to if the 'Money Week' magazine had featured a
'buy' recommendation also.

Can anyone verify whether OXB has a working partnership with Cobra Bio? If
so this could be positive news ahead of the oxb results because Cobra Bio was
up over 30% this morning.

I'm off on annual leave again next week (tee hee hee!). Well it is pointless
me being at my desk while my mind will be concentrated on the forthcoming
results.

Anyone been buying or selling this week? Anyon else still using this BB?

This BB is extinct, bereft of life, it is no more. Well, probably a slight exaggeration. Everyone continues to wait for news - not a healthy position to be in. I will check on a couple of other BB sites whether anyone knows of a link between OXB and Cobra Bio - although I have not heard of such a link previously. Enjoy your holiday 1704.